[MLL-rearranged leukemia and menin inhibitors]

Area of Science:

• Oncology
• Epigenetics
• Hematology

Background:

• Gene rearrangements of the human MLL (KMT2A) gene lead to leukemia with poor prognosis.
• MLL is an epigenetic regulator essential for maintaining HOX gene expression during development.
• MLL fusion proteins drive leukemic transformation by overexpressing HOX genes and blocking hematopoietic cell differentiation.

Purpose of the Study:

• To explain how menin inhibitors disrupt MLL fusion protein activity.
• To discuss the role of the menin-MLL interaction in MLL-driven leukemias.
• To review potential future developments in menin inhibitor therapy.

Main Methods:

• Review of scientific literature on MLL gene rearrangements, menin protein, and menin inhibitors.
• Analysis of the mechanism of action for menin-MLL interaction inhibitors.
• Discussion of clinical applications and future directions for menin inhibitors.

Main Results:

• MLL fusion proteins require menin complex formation to function as oncogenic drivers.
• Menin inhibitors disrupt the menin-MLL interaction, thereby inhibiting MLL fusion protein activity.
• Small compounds inhibiting menin-MLL interaction are approved for clinical use in the United States.

Conclusions:

• Menin inhibitors represent a targeted therapeutic approach for MLL-driven leukemias.
• Disruption of the menin-MLL interaction offers a promising strategy to treat specific types of leukemia.
• Further research into menin inhibitors may lead to improved treatment outcomes for patients with MLL gene rearrangements.